2024 World Conference on Lung Cancer (WCLC) - ePosters-EP.12C.04 Location of Metastases and Prognosis of Patients with Metastatic KRAS-Mutant Non-Small Cell Lung Cancer

EP.12C.04 Location of Metastases and Prognosis of Patients with Metastatic KRAS-Mutant Non-Small Cell Lung Cancer

Pdf Summary

The study investigates the location of metastases and prognosis of patients with metastatic KRAS-mutant non-small cell lung cancer (NSCLC) at La Paz University Hospital, using data from May 2022 to September 2023. KRAS mutations, notably KRASG12C and KRASG12V, are common in NSCLC, but their role in predicting prognosis and response to treatment remains uncertain.<br /><br />Analyzing 49 patients, mostly male with a median age of 66, the study found that most (95.9%) had a smoking history and a predominant histology of adenocarcinoma. The distribution of KRAS mutations was 32.7% for KRASG12C, 24.5% for KRASG12V, 10.2% for KRASG12D, among others. Common co-mutations included TP53 and CDKN2A.<br /><br />Metastasis locations frequently included the bone (38.8%), brain (36.7%), lungs (36.7%), liver (20.4%), pleura (26.5%), and adrenal glands (26.5%). Remarkably, bone metastasis was significantly less common among KRASG12V patients.<br /><br />Regarding treatment, 67.4% received chemoimmunotherapy, and the minority received either immunotherapy or chemotherapy alone. The overall median progression-free survival (PFS) for treated individuals was 9.02 months, while the median overall survival (OS) for all patients was 14 months. Though not statistically significant, KRASG12C and KRASG12V mutations were associated with better PFS and OS than rarer KRAS mutations. Conversely, KRASG12D mutations correlated with shorter PFS.<br /><br />In conclusion, the study suggests that KRAS-mutant patients exhibit distinct metastatic patterns based on their mutation subtype. Patients with KRASG12C and KRASG12V mutations appear to have a more favorable prognosis and benefit more from chemoimmunotherapy compared to those with KRASG12D mutations. This highlights the potential need for personalized treatment strategies for KRAS-mutant NSCLC patients based on their specific mutation profile.

Asset Subtitle

Oliver Higuera Gómez

Meta Tag

Speaker Oliver Higuera Gómez

Topic Metastatic Non-small Cell Lung Cancer – Targeted Therapy

Keywords

metastatic NSCLC

KRAS mutations

KRASG12C

KRASG12V

prognosis

adenocarcinoma

chemoimmunotherapy

progression-free survival

bone metastasis

personalized treatment